Help patients find their Zone of Control with important education and copay assistance

Educate your patients about Zohydro^® ER and help offset the cost of their prescriptions.

Eligible patients may pay as little as $15 for each prescription.*

To help support patients taking Zohydro^® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, equip them with the Find Your Zone of Control Patient Toolkit. This comprehensive resource includes a copay card, important education, and special offers to help them take, store, and protect their medication.

For any further questions about Zohydro^® ER or copay assistance, call 1-866-ZOGENIX (1-866-964-3649).

*Copay Card Program Details
Insured or insured/not covered patients can use the copay card to reduce out-of-pocket expenses on eligible prescriptions of Zohydro^® ER. Patients can present the copay card to the pharmacist along with a valid Zohydro^® ER prescription. Insured patients will pay as little as a $15 copay on each prescription. Maximum benefits apply. Good for up to 24 uses. Offer not valid for cash-paying patients. Patients are not eligible if their prescriptions are paid in part or in full by any state or federally funded programs, including but not limited to, Medicare or Medicaid, Medigap, VA, DOD, or Tricare and where prohibited by law. Offer good only in the USA and cannot be redeemed at government-subsidized clinics. Zogenix, Inc. reserves the right to rescind, revoke, or amend this offer without notice. By redeeming this offer, the patient agrees to comply with the terms and conditions as set forth above.

Click “Continue” to download a copay card for your patients.

Zohydro^® ER with BeadTek^TM

The clinical significance of BeadTek^TM and its impact on abuse/misuse liability has not been established.

Pernix Ireland Limited, a wholly owned subsidiary of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced on April 24, 2015, that it completed the acquisition of the Zohydro^® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, franchise from Zogenix, Inc. (NASDAQ: ZGNX).

You are being redirected

ZohydroER.com for patients is currently under construction. In the meantime, click Continue to visit zohydroerrems.com for information and tools to help support appropriate use of Zohydro^® ER (hydrocodone bitartrate) Extended-Release Capsules, CII.

Now approved for chronic pain -- The first and only extended-release hydrocodone -- Now you can help your chronic pain patients find their zone of control.

INDICATION

Zohydro^® ER (hydrocodone bitartrate) is an extended-release opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

LIMITATIONS OF USE

• Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Zohydro ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
• Zohydro ER is not indicated as an as-needed (prn) analgesic.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Zohydro ER is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected paralytic ileus, or hypersensitivity to hydrocodone bitartrate.

WARNINGS AND PRECAUTIONS

See Boxed WARNINGS

• Interactions with CNS Depressants: Concomitant use may cause profound sedation, respiratory depression, and death. If coadministration is required, consider dose reduction of one or both drugs.
• Elderly, Cachectic, Debilitated Patients, and Those with Chronic Pulmonary Disease: Monitor closely because of increased risk for life-threatening respiratory depression.
• Hypotensive Effects: Monitor during dose initiation and titration.
• Patients with Head Injury or Increased Intracranial Pressure: Monitor for sedation and respiratory depression. Avoid use of Zohydro ER in patients with impaired consciousness or coma susceptible to intracranial effects of CO₂ retention.
• Concomitant use of CYP3A4 inhibitors may increase opioid effects.

ADVERSE REACTIONS

• Potential serious adverse events caused by opioids include addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; interactions with other CNS depressants; hypotensive effects; gastrointestinal conditions; and seizures.
• Adverse reactions in ≥2% of patients in placebo-controlled trials include constipation, nausea, somnolence, fatigue, headache, dizziness, dry mouth, vomiting, pruritus, abdominal pain, peripheral edema, upper respiratory tract infection, muscle spasms, urinary tract infection, back pain, and tremor.
• With intravenous abuse, the inactive ingredients in Zohydro ER can result in death, local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

DRUG INTERACTIONS

• Mixed Agonists/Antagonists and Partial Agonist Analgesics: Avoid use with Zohydro ER because they may reduce analgesic effect of Zohydro ER or precipitate withdrawal symptoms.
• The use of MAO inhibitors or tricyclic antidepressants with Zohydro ER may increase the effect of either the antidepressant or Zohydro ER.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please read full Prescribing Information for the full boxed warning, complete safety information, and medication guide.

Rx Only.
DEA order form required.

ZOHYDRO^® ER with BeadTek^TM is manufactured for Pernix Ireland Pain Limited and distributed by Pernix Therapeutics, LLC., Morristown, NJ 07960. US Patent Nos.: US 6,228,398 and US 6,902,742.

ZOHYDRO^® ER is a registered trademark of Pernix Ireland Pain Limited. BeadTek^TM is a trademark used by Pernix Ireland Pain Limited under license.